[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Western Australia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100564227","treatable-traits-in-interstitial-lung-disease-100564227",false,"NCT06626438","Treatable Traits in Interstitial Lung Disease","TTRILD","Inclusion Criteria: Patients with a new or pre-existing diagnosis of fibrotic ILD who receive care via the Fiona Stanley Hospital (FSH) or Sir Charles Gairdner Hospital (SCGH) ILD service will be invited to participate. This ILD diagnosis must be made through an ILD MDT.\n\nIncluded participants will be aged ≥ 18 years with a physician-confirmed diagnosis of fibrotic ILD. Fibrotic ILD is defined as presence of fibrotic changes on CT in the opinion of the investigator. All ILD subtypes, excluding sarcoidosis, will be included. Participants will need to be able to provide consent to participate and be established on stable ILD treatment for 1 month prior to study initiation.\n\nExclusion Criteria: Participants will be excluded if they have experienced an acute exacerbation 4 weeks prior to starting the study or are expected to experience either a transplant or death during the study period. Active suicidality, severe depression, active psychosis or mania, or other severe psychiatric concerns that require more intensive treatment. Any such participants could be referred for individual therapy and\u002For psychiatric treatment that would be more appropriate for their needs.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if a personalised treatment model of care \"treatable traits\" can improve quality of life and disease progression in patients with interstitial lung disease.\n\nThe main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes).\n\nResearchers will compare the treatable traits model to standard of care.\n\nParticipants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.",[26],"Interstitial Lung Diseases (ILD)",[28,29,30,31],"treatable traits","interstitial lung disease","pulmonary fibrosis","multidisciplinary","RECRUITING","2025-10-01",{"date":35,"type":36},"2025-10-07","ACTUAL",{"date":38,"type":36},"2025-09-03",{"date":40,"type":20},"2027-07",{"name":42,"class":43},"The University of Western Australia","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100589226","investigating-visual-verticality-disorder-and-lateropulsion-in-a-neurosurgical-cohort-of-patients-with-brain-tumours-100589226","NCT06951659","Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours","Clinical, Rehabilitation and Neuroimaging Investigation of Lateropulsion, Graviceptive Neglect and Verticality Perception in Neurosurgical Patients With Brain Tumours: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients of age 18 to 80 admitted to SCGH under the neurosurgery team with a confirmed diagnosis of a brain tumour.\n* Only patients who undergo partial or full brain tumour resection and are medically stable.\n* Able to provide written informed consent or consent provided by a Research Decision-Maker with the approval of an Independent Medical Practitioner (IMP) as per the Guardianship and Administration Act 1990 (GAA).\n* Patients with a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required.\n\nExclusion Criteria:\n\n* Patients who undergo only biopsy will not be included.\n* Unable to follow any instructions and complete assessments due to significant medical deterioration.\n* Patients who are pregnant.\n* Current diagnosis of COVID-19 or respiratory syncytial virus (RSV), or any type of influenza.\n* Patients without a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required.\n* An Advanced Care Health Directive prohibiting decision making by Research Decision-Maker.","80 Years",{"count":53,"type":20},100,"30 Days","OBSERVATIONAL","The overall objective of this research is to investigate the clinical characteristics pre- and post-brain tumour resection with a focus on visual verticality disorder, and lateropulsion, including neuroimaging analysis, of a neurosurgical cohort of patients with brain tumours. This prospective observational cohort study will investigate clinical and neuroimaging characteristics and the relationship between lateropulsion and visual verticality disorder in patients pre- and post-brain tumour resection. Patients (aged 18-80 years, with a confirmed diagnosis of brain tumour and a neurosurgical pathway) will be enrolled from the state-wide Neurosurgery Service of Western Australia at Sir Charles Gairdner Hospital.",[58],"Brain Tumours",[60,61,62,63,64,65,66,67,68,69],"Brain tumour","lateropulsion","visual verticality perception","graviceptive neglect","neurosurgery","neuroimaging","structural connectivity","acute care","rehabilitation","neuro-oncology","2025-06-17",{"date":72,"type":36},"2025-06-19",{"date":74,"type":36},"2025-06-12",{"date":76,"type":20},"2025-12-30",{"name":42,"class":43},1,""]